



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

April 7, 2020: 6:30 – 8:00 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**

- **Medical Director Update** **6:40 - 6:45**

- **Follow-up Items from Previous Meetings** **6:45 - 6:50**
 - None at this time

- **RetroDUR/ProDUR** **6:50- 7:00**
 - Introduce: Concurrent Use of Opioids and Antipsychotics

- **Clinical Update: Drug Reviews** **7:00-7:45**
(Public comment prior to Board action)

Biosimilar Drug Reviews

- None at this time

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)

- Aklief® cream (trifarotene)
 - Drizalma® Sprinkle (duloxetine)
 - Duaklir® Pressair (aclidinium bromide/ formoterol fumarate)
 - Nayzilam® (midazolam)
 - Nourianz® (istradefylline)
 - ProAir® Digihaler (albuterol sulfate inhalation powder)
 - Trikafta® (elexacaftor/ivacaftor/tezacaftor) (Included in the Cystic Fibrosis TCR)
 - Vyndamax® (tafamidis)
 - Vyndaqel® (tafamidis meglumine)
 - Wakix® (pitolisant)
 - Xenleta® (lefamulin)
-
- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:00**
 (Public comment prior to Board action)
 - Cystic Fibrosis

- **Review of Newly-Developed/Revised Criteria** **8:00 - 8:00**
 (Public comment prior to Board action)
 - None at this time

- **General Announcements** **8:00 – 8:00**
 - FDA alerts patients and health care professionals of EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injector errors related to device malfunctions and user administration
https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-epipen-auto-injector-errors-related-device?utm_campaign=FDA%20alerts%20patients%20and%20health%20care%20professionals%20of%20EpiPen%20auto-injector%20errors&utm_medium=email&utm_source=Eloqua
 - FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process
https://www.fda.gov/news-events/press-announcements/fda-approves-three-drugs-nonprescription-use-through-rx-otc-switch-process?utm_campaign=022420_PR_FDA%20Approves%20Three%20Drugs%20for%20Nonprescription%20Use&utm_medium=email&utm_source=Eloqua

- **Adjourn** **8:00**